bloedingen bleeding hemorrhage
Conditions
Interventions
Patients in the study group will be treated with platelet concentrates prepared
from 3 buffy coats, patients in the control group will be treated with standard
platelet concentrates from 5 buffy coa
Sponsors
HagaZiekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Hemato-oncologic disease Expected to receive at least two platelet transfusions
Exclusion criteria
Exclusion criteria: Known immunologic refractoriness to platelets
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of days with a grade 1b+2 bleed. | — |
Secondary
| Measure | Time frame |
|---|---|
| - total number of platelets received - total number of individual buffy coats received - the 1 and 24 hour CI - the 1 and 24 hour CCI - percentage of patients with at least one bleeding grade 1b+2 according to the BSMS - percentage of patients and percentage of days per patient with at least one >= clinically relevant minor bleeding grade according to the ISTH bleeding scale - rate of HLA alloimmunization - adverse transfusion reactions - platelet transfusion interval - total number of platelet transfusions - total number of red cell and plasma transfusions - association between albumin/creatinine in urine and/or CRP and clinically relevant bleeding grades according to the BSMS - proteomics analysis (only in a selected group of AML patients in the Haga hospital) - cost benefit analysis | — |
Countries
Netherlands
Outcome results
None listed